In our prospective observational study carried out at the Vall d'Hebron University Hospital (Catalunya, Spain), the majority of cancer patients treated with immunotherapy (i.e., monotherapy of PD1/PDL1 (programmed death-ligand 1) checkpoint inhibitors) experienced adverse drug reactions (ADRs). The gene discussed is CD274; the disease is cancer.